StreetAlpha.app
Home › Stocks › TPST

Tempest Therapeutics, Inc. (TPST)

$0.29
▼ −6.18%
LAST CLOSE · NOV 20

Tempest Therapeutics develops cancer treatments, including immune cell therapies and small molecule drugs, for patients with blood cancers and solid tumors. It last closed at $0.29 on Nov 20, down 6.18% on the day. The next earnings report for TPST is expected around Mon, Mar 29, 2027. For the quarter ended Sep 2026, TPST reported EPS of -$0.21. Over its last 8 reports the stock moved an average of 9.9% the session after earnings. Over the last 12 months TPST insiders bought $1.0M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is TPST in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TPST.

Key Stats

Last 12 months
Results
Net income
−$40.6M
EPS (diluted)
−$3.16
Valuation
Market cap
$5.7M
20.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$897K
At Sep 30
Shareholder equity
−$1.8M
Shares outstanding
20.0M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$28.3M−$28.3MFY2021FY2022: −$35.7M−$35.7MFY2022FY2023: −$29.5M−$29.5MFY2023FY2024: −$41.8M−$41.8MFY2024FY2025: −$26.3M−$26.3MFY2025

From TPST's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · Time not announced
Reported EPS
-$0.21
Quarter ended Sep 2026
Year ago EPS
-$0.79
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$4.02Dec '24Mar 2025: -$3.16Mar '25Jun 2025: -$2.07Jun '25Sep 2025: -$0.79Sep '25Dec 2025: -$0.62Dec '25Mar 2026: -$2.53Mar '26Jun 2026: -$0.34Jun '26Sep 2026: -$0.21Sep '26Latest -$0.21
Revenue by quarter
Not enough quarters on file yet.
How TPST moved after its last 8 reports
Average move the session after a report ±9.9%
Nov 13, 2026After the close−10.5%
Aug 13, 2026After the close−13.3%
May 14, 2026After the close−12.4%
Mar 30, 2026Time not announced−12.1%
Nov 5, 2025Time not announced+9.1%
Aug 11, 2025After the close+10.0%
May 13, 2025After the close−3.5%
Mar 27, 2025After the close−8.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TPSTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TPST
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TPST

Technical Analysis

TPST · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 43% below its 20 day and 118% below its 50 day average. It is 364% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the 52 week low at $0.28, and the nearest resistance the Pivot at $0.29.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 17.6%/day
Key levels
$2.8352 week high+875.9%
$1.33200 day average+358.6%
$0.81100 day average+179.3%
$0.6350 day average+117.2%
$0.48Swing high (Nov 11)+65.5%
$0.4120 day average+41.4%
$0.30Pivot R1+3.4%
$0.29Pivot+0.0%
$0.29Last close
$0.2852 week low−3.4%
$0.28Pivot S1−3.4%
Indicators
RSI (14)20.67Oversold below 30Oversold
MACD-0.09Below its signal lineBearish
Stochastic4.6Near the bottom of its rangeOversold
ADX (14)30.4Trending down
Williams %R-97.0Oversold below −80, overbought above −20Oversold
CCI (20)-124.2Oversold below −100, overbought above 100Oversold
Rate of change−24.6%Change over 10 sessionsBearish
ATR (14)$0.05Typical daily range, 17.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TPST

What happened before

See how TPST did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TPST usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TPST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TPSTHow many large options trades hit TPST, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

TPST Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲10 buying vs 8 selling
  • ▼Held by funds -2.4 pts
  • ▲Funds holding +3
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2421+14.3%
In funds' top 1012−50.0%
Held by funds4.1%6.5%−2.4 pts
New / increased8 / 24 / 5+11.1%
Reduced / sold out3 / 53 / 50.0%
Put/call ratio–––
SuperinvestorsKen GriffinSold out
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TPST institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TPST Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$1.0M2 buys · 1 insider
Sold$00 sales · 0 insiders
2026-03 bought $1.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 24Matthew AngelCEO and PresidentBuy231,482$2.16$500K
Mar 24Matthew AngelCEO and PresidentBuy231,482$2.16$500K
Every insider buy and sale for TPST over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TPST insider trades →

From SEC Form 4 filings by TPST's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TPST is in one of them and how their past TPST trades turned out.

TPST in the AI portfolios
Loading…

TPST News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TPST in an article yet. Here's the latest on the wider market.

TPST in the news

About Tempest Therapeutics

Tempest Therapeutics is a biotechnology company based in Brisbane, California, that develops treatments for cancer. Its pipeline includes cell therapies that use engineered immune cells to target tumors, including a candidate for multiple myeloma, a blood cancer. It also develops small molecule drugs, including one being prepared for late-stage testing in liver cancer and another for people with a rare inherited condition that raises the risk of certain cancers. Its candidates are still in development and not approved for sale, and they are aimed at patients with these cancers and conditions.

Headquarters
Brisbane, CA